1177 Panoramica delle azioni Sino Biopharmaceutical Limited, una holding di investimento, opera come conglomerato farmaceutico di ricerca e sviluppo nella Repubblica Popolare Cinese. Maggiori dettagli
Premi Analisi del rischio Non sono stati rilevati rischi per 1177 dai nostri controlli di rischio.
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Sino Biopharmaceutical Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Sino Biopharmaceutical Prezzi storici delle azioni Prezzo attuale dell'azione HK$2.98 Massimo di 52 settimane HK$4.25 Minimo di 52 settimane HK$2.29 Beta 0.68 Variazione di 1 mese -10.51% Variazione a 3 mesi -21.37% Variazione di 1 anno -10.24% Variazione a 3 anni -50.08% Variazione a 5 anni -60.58% Variazione dall'IPO 23.25%
Notizie e aggiornamenti recenti
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21 Vedi altri aggiornamenti
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21
Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States Nov 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Oct 21
Key Executive recently sold HK$51m worth of stock Oct 07
First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023) Sep 28
Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO Sep 27
Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024 Sep 16
Upcoming dividend of HK$0.03 per share Sep 03
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma Aug 28
First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023) Aug 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma Aug 01
Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024 Jul 31
Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule Jul 18
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Jul 16
Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet Jul 15
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection Jun 25
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)" Jun 19 Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director Jun 06
Upcoming dividend of HK$0.03 per share Jun 04
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma May 24
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China May 10
Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022) May 01
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules May 01
Executive Chairwoman of the Board recently bought HK$5.8m worth of stock Apr 21
Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024 Mar 29
Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022) Mar 29
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024 Mar 28
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" Mar 16
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet Mar 13
Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 02
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart Feb 28
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion. Feb 08
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) Jan 23
Now 21% undervalued Jan 15
Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain Dec 28
Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma Dec 22
Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722 Dec 12
Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038 Dec 05
An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million. Nov 10
Investor sentiment improves as stock rises 16% Oct 30
Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug Oct 17 An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 11
Upcoming dividend of HK$0.02 per share at 2.7% yield Sep 27
Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA Sep 26
First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022) Aug 26
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023 Aug 26
Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 03
Key Executive recently bought HK$34m worth of stock Jul 04
Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms Jul 01
Upcoming dividend of HK$0.06 per share at 3.0% yield Jun 13
Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine May 24
Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection) May 11
Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock Apr 06
Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021) Apr 01
Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation Feb 11
Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer Jan 14
Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203" Dec 10
Less than half of directors are independent Nov 16 Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
Upcoming dividend of HK$0.06 per share Aug 30
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022 Aug 24
First half 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 1H 2021) Aug 24
Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022 Aug 12 Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule Jun 28
Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial Jun 15
Upcoming dividend of HK$0.04 per share Jun 08
Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139" May 24
Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020) May 02
Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial Apr 21
Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication Apr 20
Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE Apr 09
Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China Apr 08
Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020) Apr 02 Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022
Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHND5071 Obtained Approval for Clinical Trial Mar 30
Investor sentiment improved over the past week Mar 22
Sino Biopharmaceutical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022 Mar 03
Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing Jan 22
Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate Granted by National Medical Products Administration Jan 12
Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial Dec 22
Founder & Senior Vice Chairman recently bought HK$29m worth of stock Oct 08
VP & Executive Director recently bought HK$12m worth of stock Sep 22
Second quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.019 in 2Q 2020) Sep 02
Founder & Senior Vice Chairman recently bought HK$101m worth of stock Sep 02
Akeso, Inc. and Sino Biopharmaceutical Limited Announces Penpulimab Monoclonal Antibody Marketing Approval in China Aug 08
Founder & Senior Vice Chairman recently bought HK$98m worth of stock Jul 28
Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injection" Obtains Drug Registration Certificate Jul 16 Rendimenti per gli azionisti 1177 HK Pharmaceuticals HK Mercato 7D -3.6% -2.7% -1.7% 1Y -10.2% -8.1% 16.5%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 1177 ha trovato corrispondenza nel Hong Kong Pharmaceuticals che ha restituito -8.1 % nell'ultimo anno.
Rendimento vs Mercato: 1177 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 16.5 % nell'ultimo anno.
Volatilità dei prezzi Is 1177's price volatile compared to industry and market? 1177 volatility 1177 Average Weekly Movement 3.5% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 6.8% 10% most volatile stocks in HK Market 14.5% 10% least volatile stocks in HK Market 3.2%
Prezzo delle azioni stabile: 1177 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Hong Kong.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di 1177 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Sino Biopharmaceutical Limited, una holding di investimento, opera come conglomerato farmaceutico di ricerca e sviluppo nella Repubblica Popolare Cinese. Opera attraverso tre segmenti: Farmaci cinesi modernizzati e farmaci chimici, Investimenti e Altri. L'azienda offre farmaci oncologici, tra cui le capsule di anlotinib cloridrato con il marchio Focus V, l'iniezione di penpulimab con il marchio Annike, l'iniezione di efbemalenograstin alfa con il marchio Yilishu, le capsule di pomalidomide con il marchio Anyue, l'iniezione di bevacizumab con il marchio Anbeisi, l'iniezione di rituximab con il marchio Delituo e il trastuzumab per iniezione con il marchio Saituo; farmaci per le malattie epatiche, come l'isoglicirrizinato di magnesio iniettabile con il marchio Tianqing Ganmei e le compresse dispersibili di entecavir con il marchio Runzhong; e farmaci per il sistema respiratorio, tra cui la sospensione di budesonide per inalazione con il marchio Tianqing suchang e il colistimetato sodico per iniezione con il marchio Tianyun.
Mostra di più Sino Biopharmaceutical Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Sino Biopharmaceutical con la sua capitalizzazione di mercato? 1177 statistiche fondamentali Capitalizzazione di mercato HK$54.25b Guadagni(TTM ) HK$2.27b Ricavi(TTM ) HK$29.49b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 1177 Conto economico (TTM ) Ricavi CN¥27.79b Costo del fatturato CN¥5.23b Profitto lordo CN¥22.56b Altre spese CN¥20.41b Guadagni CN¥2.14b
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.12 Margine lordo 81.16% Margine di profitto netto 7.71% Rapporto debito/patrimonio netto 22.6%
Come si è comportato 1177 nel lungo periodo?
Vedi performance storica e confronto Dividendi
1.9% Rendimento attuale del dividendo
47% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/09 11:10 Prezzo dell'azione a fine giornata 2025/01/09 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Sino Biopharmaceutical Limited è coperta da 51 analisti. 23 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Justin Liu BNP Paribas Securities (Asia) Ling Zhang BNP Paribas Securities (Asia) Wai Chak Yuen BOCI Research Ltd.
Mostra 48 altri analisti 
